mepolizumab (Nucala)

following an abbreviated submission:

mepolizumab (Nucala®) is accepted for restricted use within NHSScotland.

Indication under review: as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.

SMC restriction: patients who have eosinophils of at least 150 cells per microlitre (0.15 x 109/L) at initiation of treatment and have had at least three asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids.
Mepolizumab offers an additional treatment choice in the therapeutic class of monoclonal antibodies.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice supersedes SMC advice for mepolizumab as an add-on treatment for severe refractory eosinophilic asthma in adult patients (SMC 1149/16) and adolescents and children aged 6 years or older (SMC2139).